Squalene synthase inhibitors suppress triglyceride biosynthesis through the farnesol pathway in rat hepatocytes Published, JLR Papers in Press, October 16, 2002. DOI 10.1194/jlr.M200316-JLR200

@article{Hiyoshi2003SqualeneSI,
  title={Squalene synthase inhibitors suppress triglyceride biosynthesis through the farnesol pathway in rat hepatocytes Published, JLR Papers in Press, October 16, 2002. DOI 10.1194/jlr.M200316-JLR200},
  author={H. Hiyoshi and M. Yanagimachi and M. Ito and N. Yasuda and T. Okada and H. Ikuta and D. Shinmyo and Keigo Tanaka and N. Kurusu and I. Yoshida and S. Abe and T. Saeki and H. Tanaka},
  journal={Journal of Lipid Research},
  year={2003},
  volume={44},
  pages={128 - 135}
}
  • H. Hiyoshi, M. Yanagimachi, +10 authors H. Tanaka
  • Published 2003
  • Medicine, Biology
  • Journal of Lipid Research
  • We recently demonstrated that squalene synthase (SQS) inhibitors reduce plasma triglyceride through an LDL receptor-independent mechanism in Watanabe heritable hyperlipidemic rabbits (Hiyoshi et al. 2001. Eur. J. Pharmacol. 431: 345–352). The present study deals with the mechanism of the inhibition of triglyceride biosynthesis by the SQS inhibitors ER-27856 and RPR-107393 in rat primary cultured hepatocytes. Atorvastatin, an HMG-CoA reductase inhibitor, had no effect on triglyceride… CONTINUE READING
    43 Citations
    9-oxo-10(E),12(E)-Octadecadienoic acid derived from tomato is a potent PPAR α agonist to decrease triglyceride accumulation in mouse primary hepatocytes.
    • 48
    Regulation of Fatty Acid Synthesis by Farnesyl Pyrophosphate*
    • 27
    • PDF
    Farnesol, an isoprenoid, improves metabolic abnormalities in mice via both PPARα-dependent and -independent pathways.
    • T. Goto, Y. Kim, +12 authors T. Kawada
    • Biology, Medicine
    • American journal of physiology. Endocrinology and metabolism
    • 2011
    • 39
    • PDF

    References

    SHOWING 1-10 OF 61 REFERENCES
    RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase.
    • 64
    Squalene synthase inhibitors reduce plasma triglyceride through a low-density lipoprotein receptor-independent mechanism.
    • 32